Are Inhalation Drugs the Next OIG Six Year Lookback Audit?

Published in Billing, Reimbursement, Audits and Compliance on November 12, 2019

Since 2010, the CMS’s Comprehensive Error Rate Testing (CERT) program has identified nebulizers and related drugs (i.e., inhalation drugs) among the top 20 supplies with the highest improper Medicare payments. Based on prior reviews, the Office of Inspector General (OIG) conducted a nationwide review to determine if the suppliers included in the review complied with Medicare requirements when billing for inhalation drugs.

The OIG’s claims universe included 2.3 million claim lines, totaling $259.5 million, for inhalation drugs that 7,868 suppliers provided to Medicare beneficiaries during the audit period. Using statistical analysis, the OIG calculated a stratified random sample of 120 claim lines for review. Of the claim lines reviewed, Medicare paid 65 suppliers $121,185.

What did the OIG’s review uncover? According to the OIG report, not all suppliers complied with Medicare requirements when billing for inhalation drugs. For 81 of the 120 sampled claim lines, suppliers complied with the requirements; however, for the remaining 39 claim lines, 22 suppliers did not comply with documentation requirements. Based on the sample results, the OIG found an estimated $92.5 million was improperly paid to suppliers for inhalation drugs.

If you think this sounds familiar, you are right. Not too long, in 2018, the OIG performed a simliar audit on PAP Supplies. Using statistical analysis a small sample of suppliers’ claims for PAP suppliers were reviewed, and the findings projected to the universe equaled over $600 million in improperly paid claim for PAP supplies. More importantly, however, is how the OIG advised the CMS and its contractors to impose self-audits for a six year lookback period.

OIG recommendations for the inhalation drugs audit include instructing the MACs to recover the actual overpayments of $36,825 for the unallowable claims lines and to “notify the 22 suppliers associated with the 39 claim lines with potential overpayments of $36,825 so that those suppliers can exercise reasonable diligence to investigate and return any identified overpayments.” This likely means these 22 suppliers will soon receive notices from Noridian and CGS advising them to “review claims submitted related to inhalation drugs to determine if overpayments exist within the 6 year lookback period.”

If you are a supplier of nebulizers and inhalation drugs it is likely you will see increased audit activity in the near future. The Supplemental Medical Review Contractor (SMRC) often conducts audits at the direction of CMS and the OIG. The MACs may also add inhalation drugs to their audit focus, by way of TPE audits.

Could you be subject to additional audits? Here’s what you need to know: 

  • Get ahead of it now. Review your claims and perform internal reviews to prepare for this audit. 
  • If you receive a request letter, read and understand exactly what is being requested and provide what they are asking.  You may only get once chance at this.
  • Only one claim deemed overpaid by the OIG may require a 100% claim review of six-years of claims.

Do you provide nebulizers and inhalation drugs?

Look-back reviews can be burdensome and require an expert statistician. The van Halem Group will work in conjunction with your legal counsel and our doctorate level statisticians to provide an accurate and thorough audit response. In addition to statistical analysis, our clinical experts will conduct a review of the identified claims to determine coverage and documentation requirements are met. 

For more information on how we can help with these audits, or anything else, contact us today!

From Our Experts

CMS Announces Temporary Gap Period Coming in 2024 thumbnail CMS Announces Temporary Gap Period Coming in 2024 CMS finally released the notice with details regarding the competitive bidding program (CBP) and a temporary gap period. CMS has done this same process in the past prior to the 2021 CBP round. Reducing Medicare Payments for Urinary Catheters thumbnail Reducing Medicare Payments for Urinary Catheters The Office of Evaluation and Inspection, a component of OIG (Office of Inspector General) and HHS (Health and Human Services), recently released "Reducing Medicare's Payment Rates for Intermittent Urinary Catheters Can Save the Program and Beneficiaries Millions of Dollars Each Year,” a study that was performed on urinary catheters. An Open Discussion About Opportunities in the Diabetic Market, CGM Audits, and Reimbursements thumbnail An Open Discussion About Opportunities in the Diabetic Market, CGM Audits, and Reimbursements In this episode of Industry Matters, we talk with president of The van Halem Group, Wayne van Halem, and sales manager for GEMCO, Joseph Ault, about CGM audits, qualifications for reimbursement and documentation, as well as the opportunities in the diabetic market. Featured Service: The van Halem Group thumbnail Featured Service: The van Halem Group There's been a lot of questions and confusion surrounding telehealth services and how they relate to DMEPOS claims. This article by Wayne van Halem, originally featured in “VGM Playbook: Technology and the Patient Care Continuum Guide to Remote Work,” addresses whether or not telehealth services can be used to qualify a patient for an item of DMEPOS during the PHE. Return of the Audits thumbnail Return of the Audits HME Business recently wrote about the news that CMS planned to resume audits by Aug. 3 and that it took many by surprise. Then CMS said it would resume audits in a phased approach. What are the details and what can providers expect? CMS Audits Resume August 3, 2020 thumbnail CMS Audits Resume August 3, 2020 In this episode, we chat with Wayne van Halem and Kelly Grahovac of The van Halem Group about the CMS audits returning today, August 3, and what DMEPOS providers need to know. Member Q&A From The van Halem Group: New Order Requirement and Member Q&A From The van Halem Group: New Order Requirement and "Master List" I'm curious about this new order requirement. I see that Medicare updated the notice on 2/12/20, and I'm curious about the “Master List” of items that still needs a WOPD. I'm wondering if PAP equipment and supplies fall under the SWO or the WOPD. Can you help me understand? The Cost of Compliance – An Impassioned Plea to be Proactive thumbnail The Cost of Compliance – An Impassioned Plea to be Proactive Last year, The van Halem Group was engaged by several DME providers that were subject to a 6-year OIG lookback audit. Sadly, for companies that did not have a process in place for proactive chart audits, the 6-year look back resulted in a very expensive lesson. Lookback audits are here to stay, and it's never been more important for providers to have a comprehensive proactive compliance program, and this is one way that The van Halem Group can assist members.